Agenda Overview –
– Evidence and Health Technology Assesment – Terms, Concepts, and Landscape
– What Is Cost-Effectiveness
– Methods of Cost-Effectiveness Analysis
– Opportunities and Risks of Cost-Effectiveness Data
– Cost-Effectiveness in Different Product Types and Therapeutic Categories
– Policy Makers and Cost-Effectiveness Around the World
– Panel Discussion: Strategic, Tactical, and Business Considerations
– Internal Resources
– Case Study: Using Cost-Effectiveness Data in a Coverage Decision
– Case Study: Percutaneous Heart Assist
– Case Study: Deep Brain Stimulation
– Case Study: The Drug-Eluting Stent
– General Discussion
Speakers –
– Parashar Patel, Vice President, Health Economics and Reimbursement, Boston Scientific
– Gregory de Lissovoy, Senior Research Scientist, Vice President of Health Technology, United BioSource
– John Hermandez, Vice President, Neuromodulation, Health Economics and Reimbursement, Boston Scientific
– Bonnie Handke, Senior Director, Neuromodulation Reimbursement, Medtronic
– William Sarraille, Partner, Sidley Austin
– Thomas Goss, Vice President, Boston Healthcare Associates
– Liesl Cooper, VP, Global Healthcare Economics, Policy & Reimbursement, Medical Devices, Covidien
– Richard Toselli, Worldwide VP of Clinical Evidence & External Relations, DePuy Spine, a J&J Company
– Ramy Mahmoud, Chief Medical Officer, World Wide Vice President, Evidence Based Medicine, Ethicon, Inc.
– Andrew Greenfield, VP, Healthcare Solutions, Abiomed, Inc.